Cellectar biosciences announces pricing of $24.5 million underwritten public offering and $20.5 million concurrent private placement

Florham park, n.j., dec. 23, 2020 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.
CLRB Ratings Summary
CLRB Quant Ranking